The criteria for ≥50% CMAP amplitude reduction was only fulfilled by CIDP patients (6 nerves) and CIDP +DSP (13 nerves). This evidence concerns the gene PMP22 and chronic inflammatory demyelinating polyradiculoneuropathy.